British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) has been approved by the US Food and Drug ...

The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...

Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a ...

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant ...

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...

DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or ...

AstraZeneca announced on Monday that it has secured approval from the US Food and Drug Administration, alongside Daiichi ...

BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...